Fig. 1: CRABP2 and FABP5 expression patterns in the ATC cell lines with and without RA treatment. | npj Precision Oncology

Fig. 1: CRABP2 and FABP5 expression patterns in the ATC cell lines with and without RA treatment.

From: ZEB1 and ALKBH5 coregulate CRABP2 and FABP5 and jointly determine the sensitivity of anaplastic thyroid cancers to gemcitabine and retinoic acid

Fig. 1: CRABP2 and FABP5 expression patterns in the ATC cell lines with and without RA treatment.

A WB analysis of CRABP2 and FABP5 expression in the 8505 C, Cal62, HTH7, THJ-11T, THJ-16T and THJ-21T cell lines. B CCK8 assays were performed on 8505 C, Cal62, HTH7, THJ-11T, THJ-16T, and THJ-21T cells cultured normally (N) or treated with 0.2% DMSO or 10 μM RA for 48 h (RA). C Immunocytochemical staining of CRABP2 and FABP5 in the three cell lines with no treatment (N) or with 48 h of 10 μM RA treatment (RA). D Immunofluorescence staining of CRABP2 and FABP5 in the three cell lines with no treatment (N) or with 48 h of 10 μM RA treatment (RA). Green, CRABP2; red, FABP5. Merge, overlapping green and red staining. qRT-PCR (E) and WB analyses (F) of CRABP2 and FABP5 expression in THJ-11T, THJ-16T, and THJ-21T cells with no treatment (N) or with 10 μM RA treatment for 48 h (RA). The molecular weights of CRABP2 and FABP5 were 16 and 15 kDa, respectively. Band density was quantified by ImageJ and normalized to the level of GAPDH as the loading control. N.S., nonsignificant. Scale bar, 5 mm. The data in A and B were analyzed by one-way ANOVA. The data in (C–F) were analyzed by t tests. Images from WB, ICC staining and IF staining experiments are representative of three independent experiments. *p < 0.05, **p < 0.01 indicate statistical significance.

Back to article page